Why Eli Lilly Stock Is Crushing It Today

Shares of the biopharmaceutical giant Eli Lilly (NYSE: LLY) jumped by as much as 20% in pre-market trading Monday morning. The drugmaker's shares are shooting higher in response to a positive clinical update for its experimental Alzheimer's disease drug known as donanemab.

Donanemab is an experimental antibody designed to target a modified form of beta amyloid. In a midstage trial, the drug reportedly produced a statistically significant slowing in the decline in both cognition and daily function in patients with early symptomatic Alzheimer's disease, when compared to individuals receiving a placebo. 

Image source: Getty Images.

Continue reading

Source Fool.com